Literature DB >> 7456197

Bilateral orchiectomy for carcinoma of prostate. Response of serum testosterone and clinical response to subsequent estrogen therapy.

R C Klugo, R N Farah, J C Cerny.   

Abstract

Forty-five patients with symptomatic Stage D carcinoma of the prostate were treated with bilateral orchiectomy. Serum testosterone levels were obtained before orchiectomy, seven days after and a six-month intervals. With relapse after orchiectomy remission patients were treated with diethylstilbesterol (DES) 1 mg. daily. After bilateral complete orchiectomy 40 patients had serum testosterone levels in the anorchic range (21.5 to 39.7 ng./dl) while 5 had testosterone levels between 117 and 187 ng./dl. The mean remission response after orchiectomy was 9.1 months (three to twenty-four months) in the anorchic group and 9.4 months in the imcomplete anorchic group. Mean relapse response to estrogen therapy in the anorchic group was four months (one to six months). While in the incomplete anorchic group mean relapse response to estrogen therapy was 20.8 months (one to sixty). Serum testosterone levels in the imcomplete group decreased with estrogen therapy while those in the anorchic group were stable with estrogen therapy. Our findings suggest that bilateral complete orchiectomy does not always provide serum testosterone levels in the anorchic range. Subsequently these patients show an improved mean response to oral estrogen therapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7456197     DOI: 10.1016/0090-4295(81)90011-x

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

1.  The cost and availability of therapeutic options in advanced prostatic carcinoma in Turkey.

Authors:  N Y Ilker; O Dillioğlugil; A Akdaş
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

2.  Prostatic carcinoma.

Authors:  D Kirk
Journal:  Br Med J (Clin Res Ed)       Date:  1985-03-23

3.  Comparison of efficacy and safety of 1- and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer.

Authors:  Osamu Ishizuka; Osamu Nishizawa; Shuji Nishizawa; Tomoya Satoh; Masahisa Wajiki; Hideo Kiyokawa; Yoshihiro Inoue; Shinya Kobayashi; Hiroya Mizusawa; Tatsuo Nakagawa
Journal:  Int J Clin Oncol       Date:  2012-05-03       Impact factor: 3.402

4.  Aggressive prostate cancer is prevented in ERαKO mice and stimulated in ERβKO TRAMP mice.

Authors:  Anna Slusarz; Glenn A Jackson; J Kevin Day; Nader S Shenouda; Jennifer L Bogener; Jim D Browning; Kevin L Fritsche; Ruth S MacDonald; Cynthia L Besch-Williford; Dennis B Lubahn
Journal:  Endocrinology       Date:  2012-06-29       Impact factor: 4.736

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.